Immunomet therapeutics announces closing of series b. Zotatifin, currently being tested in patients with solid tumors, is a small molecule inhibitor of. The financing was led by altitude life science ventures, along with abbvie biotech ventures and biomed ventures. Antibody potency, effector function, and combinations in.
A phase ii, openlabel study of tomivosertib eft508 added on to continued checkpoint inhibitor therapy in patients pts with insufficient. Effector therapeutics funding, financials, valuation. The importance of translation regulation in disease is becoming increasingly recognized in the pharmaceutical industry, and we believe we are at the forefront of discovering novel. Jul 24, 2017 san diego, july 24, 2017 effector therapeutics, inc. Century therapeutics general information description. Effector therapeutics is pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer. The companys investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. Jan 09, 2020 by mark terry pfizer and effector therapeutics inked a global license and collaboration deal to develop smallmolecule inhibitors of eukaryotic initiation factor 4e, also known as eif4e. Pvi is delighted to further support effectors efforts to develop a promising novel class of investigational compounds for the treatment of. Our integrated technologies, designed to be the best for therapeutic use, offer key advantages. The companys drugs are geneticallyengineered, ipscderived immune effector cell products designed to specifically target hematologic and solid cancers by harnessing the power of adult stem cells, enabling patients to have access.
Despite the identification of several effector t cell t effdriving transcription factors tfs, the transcriptional coordination of t eff biology remains poorly understood. Venture partners, abingworth, novartis venture funds, sr one, altitude ventures, astellas venture management, and abbvie ventures. Mnk12 play a crucial role in the development of many tumors, including by controlling in a coordinated manner the expression of multiple factors that attenuate an immune response. The atlas effectors of antitumor immunity is a unique scientific publication, which. Developer of allogeneic living drugs designed to overcome the limitations of firstgeneration cell therapies. Physical and functional interactions between mnk and mtor signaling regulate the activation and differentiation of t cells. Developer of a drug discovery platform designed to target the solute carrier slc family of transporters and cells metabolic gates. Their latest funding was raised on may, 2019 from a venture series unknown round. Effector therapeutics company profile office locations. The financing was led by existing investor incon co. Tomivosertib also known as eft508 is a novel, potent and highly selective oral small molecule inhibitor of mitogenactivated protein kinase interacting kinases 1 and 2, or collectively, mnk12.
Pfizer venture investments pvi led the round and was joined by additional new investors including alexandria venture investments. The funds will be used to support discovery programs and enable acquisition of tumor response data in patients for a lead drug candidate the company said. Discovery and characterization of novel nonsubstrate and substrate nampt inhibitors. Pvi is delighted to further support effectors efforts to develop a promising novel. Fortis was founded on technology from bin liu, a professor at uc san francisco. The financing was led by altitude life science ventures, along with abbvie biotech. Tomivosertib inhibits mnk12,a central regulator of immune attenuation. Oct 24, 2000 check out effector by download on amazon music. About us effector therapeutics is a clinicalstage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation. Effector therapeutics, a company spun out from the university of california, san francisco to develop a smallmolecule drug to combat the.
Atlas effectors of antitumor immunity springerlink. The companys platform uses myeloid cells versatile cells with effector functions capable of targeting and eliminating cancerous cells, along with other harmful cells in the body, thereby enabling medical practitioners to overcome many. Six webinars are planned throughout 2020 and include the following topics. Aacrncieortc international conference on molecular targets and cancer therapeutics 2019. San diego, july 24, 2017 prnewswire effector therapeutics, inc. Effector therapeutics is an earlystage company focused on the discovery and. Aberrant protein translation plays a role in the pathogenesis of multiple solid tumors and hematological malignancies. The translation initiation factor eif4e is essential for the translation of m. Jul 24, 2017 about effector therapeutics effector therapeutics is a clinicalstage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small. Jnana therapeutics general information description. Venture partners, abingworth, novartis venture funds, sr one, astellas venture management, osage university partners and mission bay capital. Pfizer venture investments pvi led the round and was joined by additional new investors including alexandria venture. Jul 24, 2017 local biotech effector therapeutics inc. Zeno pharmaceuticals in its series a and series b financings for undisclosed amounts.
Development of adaptive immune effector therapies in solid tumors. The research on the drug is in collaboration with big pharma partners pfizer and merck kgaa. Aug 23, 2017 san diego, july 24, 2017 prnewswire effector therapeutics, inc. See insights on effector therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at craft. The state of fact immune effector cell therapy accreditation today presented by dr. Novel cancer antigens for personalized immunotherapies. Feb 19, 2016 san diego, february 19, 2016 effector therapeutics, inc. Tp said the round was coled by lilly asia ventures lav, orbimed advisors llc, and s. The money comes from private investors including hiroshi mikitani, the ceo of japanbased rakuten inc. Just the facts fact news fact announces immune effector.
About effector therapeutics effector therapeutics is a clinicalstage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small. The companys investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving. Improving effector activity of antigenspecific t cells is a major goal in cancer immunotherapy. The column group and astellas venture management are the most recent investors. The fact education committee and immune effector cell task force have developed a series of webinars on immune effector cellular therapy.
Private company effector therapeutics is a clinicalstage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer. Antibody potency, effector function, and combinations in protection and therapy for sarscov2 infection in vivo j exp med. The series c proceeds will also enable the company to advance eft226. Company profile page for effector therapeutics inc including stock price, company news, press releases, executives, board members, and contact information.
Our goal is to provide our novel treatments to patients as quickly as possible, but in a way that stands up to scientific rigor and achieves the best clinical outcomes. Jul 25, 2017 by effector therapeutics jul 24, 2017, 08. Zotatifin, a small molecule that effector therapeutics is testing in cancer clinical trials, may also be effective against the novel coronavirus. San diego biotechs antitumor molecule slows coronavirus, lab. Gcapped mrna and is a key point of convergence for several signaling pathways, such as pi3kmtor and mapk. Investors bregua corporation, lilly asia ventures, osage university partners, and vivo capital joined the round. We developed an in vivo t cell crispr screening platform and identified a key mechanism restraining t eff biology through. Even in what seems like the greatest despair, you can find hope. Sep 27, 2016 san diego life science upstart fortis therapeutics inc.
The new money will be used to advance a cancer drug called eft508 into phase 2 trials. Myeloid therapeutics general information description. Developer of proteinsynthesis drugs intended to focus on pioneering the discovery and development of a new class of oncology medicines known as selective translation regulators strs. Major properties of dendritic cells and their actual and potential applications in cancer therapy and infectious disease pro. Purchase therapeutic antibody engineering 1st edition. A phase ii, openlabel study of tomivosertib eft508 added on to. Roberta misasi, isao hozumi, takashi inuzuka, antonella. Cancers free fulltext chimeric antigen receptor car. Effector therapeutics inc 11180 roselle st san diego, ca.
24 1506 1126 242 717 986 5 84 50 1605 178 919 708 1869 622 976 899 1236 542 750 94 1844 1758 736